Search Result for : Lupin

The Dollar Business Bureau Lupin Limited (Lupin), a transnational pharma company, announced on Wednesday that its US-based subsidiary Lupin Pharmaceuticals, Inc (LPI) has got the final approval from FDA for its Armodafinil Tablets, used in treatment of obstructive sleep apnea. “Company’s US subsidiary Lupin Pharmaceuticals, Inc has received final approval for its Armodafinil Tablets 50 mg, 150 mg, 200 mg and 250 mg from the United States Food and Drug Administration (FDA) to market a generic version of Cephalon, Inc’s Nuvigil® Tablets 50 mg, 150 mg, 200 mg and 250 mg,” Lupin said in a release. LPI shall start promoting the products in the US market shortly, it added. The pharma major’s Armodafinil tablets in 250 mg, 200 mg, 150 mg and 50 mg are ...

The Dollar Business Bureau What is said to be the biggest investment by an Indian pharmaceutical major in Europe following the Brexit outcome, Ahmedabad-based Intas has acquired Actavis Generics in the United Kingdom and Ireland for £600 million (around Rs.5100 crore) from Israel's Teva in an all-cash deal. A part of the European Commission's anti-trust divestiture needs emerging from Teva acquisition of Actavis Generics from Ireland-based Allergan unit for $40 billion, the transaction would enable the Indian drug major to tap a high-potential and always-growing UK and Ireland generics markets. This deal will prompt the company to undertake expansion-related initiatives, and it is expected that the company will add one more manufacturing capability to its existing three plants in the UK, ...

The Dollar Business Bureau Lupin Ltd. on Monday announced it has received approval from the Central Drugs Standard Control Organisation (CDSCO) to introduce Acotiamide 100 mg indigestion tablets in India. The introduction of the Acotiamide drug into the Indian pharmaceutical market is likely to benefit millions of patients suffering from Indigestion or Dyspepsia. Acotiamide strengthens gastric emptying and gastric accommodation: the factors implicated for functional dyspepsia. "Acotiamide is a first-in-class novel drug to be introduced into the Indian pharmaceutical market which could benefit millions of patients suffering from dyspepsia or indigestion, amongst the most common stomach complaints encountered in clinical practice," Lupin said in a statement. “We have a rich legacy of having introduced novel treatments to address unmet medical needs in the country. I am sure ...

The Dollar Business Bureau India’s major pharmaceuticals companies are now looking to acquire niche product portfolios in several regulated markets across the world, indicated a report on Tuesday. "Recently, selected innovators have taken a call to exit their generics business and concentrate on branded/patented businesses creating billion dollar acquisition opportunities for large Indian pharma players in the regulated markets," said the report published by ICICI Securities. The country’s largest ten pharmaceutical companies, which are incidentally cash-rich, are hungry to acquire companies with their niche product portfolios. The report pointed out that the top Indian pharma companies have plethora of funds, and they can raise capital easily from debt and equity capital markets. In September, UCB sold Kremers Urban to Lannett for $1.23 billion and India-based generics portfolios ...

The Dollar Business Bureau Pharmaceutical major Lupin Ltd has entered into the branded pharma market of Japan by acquiring 21 long-listed products from Japanese company Shionogi & Co Ltd, through its arm Kyowa Pharmaceutical Industry Co Ltd. As per the terms of deal, Kyowa Pharmaceutical will start booking sales of the 21 products post December 1, 2016. Shionogi will get 15.4 billion yen (around $150 million) from Kyowa Pharmaceutical.  The deal is subject to various conditions and regulatory permissions that include transferring of marketing authorisation of the 21 products to Kyowa. “With the aim to grow worldwide as a drug discovery-based pharma company, Shionogi is utlising its resources on major areas of marketing and therapeutic, whereas continuing to develop innovative drugs to help future growth and to enhance its business ...

The Dollar Business Bureau Amid concerns over USFDA’s observations on its Goa facility, Lupin Pharma’s stocks dipped by 9% on Friday. Though the Mumbai-based pharma, on Thursday, reported 47% rise in net profit and 34% increase in sales, including its US business, the stocks saw a dip. While the drug making company said that its growth in US market will continue, it failed to attract investors. On Friday, the BSE stocks of the company closed at Rs.1,505.15, which means a fall of 9% when compared to the previous close. In the last three months, the stocks of Lupin dipped by 20%. Earlier in March, nine critical observations were made by USFDA on the Goa plant of Lupin. The company is likely to resolve the issues ...

The Dollar Business Bureau The government on Monday gave its nod to four new proposals of foreign direct investment (FDI) worth Rs.384.45 crore, while rejected an equal number of requests and deffered five others. Among those got clearance, two are related to pharmaceuticals sector and one each to defence and manufacturing. The clearance came based on the recommendations of the Foreign Investment Promotion Board (FIPB) in its meeting held on October 19. “…The government of India has approved four (04) proposals of Foreign Direct Investment (FDI) amounting to Rs.384.45 crore,” a Finance Ministry statement said. Pharma major Lupin got approval for its Rs.331.64-crore proposal. The company had sought approval in respect of ESOPs (Employees Stock Ownership Plans) issued before June 11, ...

The Dollar Business Bureau India’s generic drug market is expected to cross $27.9 billion and would account for 85% share in the domestic drug market by 2020, according to a study undertaken by ASSOCHAM and RNCOS. The current generic market size is $13.1 billion and is growing at a CAGR of about 16.3%, primarily due to approval granted by the USFDA makers and 21 drugs patent losing licenses by 2019, the study said. “Generic drugs account for 75% of the domestic pharmaceutical market by value. Drugs for cholesterol control, pain management, anticoagulant, respiratory, liver disorders, depression and lipid regulators are highly prevalent in the global market,” said the Associated Chambers of Commerce and Industry of India (ASSOCHAM) and RNCOS. The study was conducted on ‘Generic ...